GlassScriptPhysician profile
Harjinder S Chowdhary
NPI 1205942836
$13,260.06
in general payments reported to CMS, 2019-2025
40 companies · $2,424 in 2025
The $2,424 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,824 · 2020: $1,396 · 2021: $1,829 · 2022: $1,675 · 2023: $2,067 · 2024: $2,045 · 2025: $2,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,065 · Education: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,064.97 |
| Education | $471.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,843.91 | 2019-2025 | Evenity, Enbrel, Otezla |
| Mallinckrodt Hospital Products INC. | $1,458.01 | 2020-2025 | Acthar |
| Abbvie INC. | $1,408.83 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,323.61 | 2019-2025 | Tremfya, Remicade, Simponi Aria |
| Pfizer INC. | $934.92 | 2019-2025 | |
| Ucb, INC. | $800.16 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $536.02 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $535.64 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $443.05 | 2019-2024 | Ofev, Cyltezo |
| Genentech USA, INC. | $395.85 | 2019-2025 | Actemra, Rituxan |
| Astrazeneca Pharmaceuticals LP | $391.83 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $388.49 | 2019-2025 | Orencia, Sotyktu |
| Horizon Therapeutics Plc | $362.00 | 2019-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $250.14 | 2019-2025 | Ultomiris, Strensiq |
| Sobi, INC | $237.26 | 2019-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $230.52 | 2020-2025 | Taltz, Zepbound |
| Aurinia Pharma U.S., INC. | $186.31 | 2021-2025 | Lupkynis |
| Organon LLC | $143.42 | 2021-2025 | Hadlima, Renflexis |
| Mallinckrodt Enterprises LLC | $134.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.10 | 2022-2025 | Cuvitru |
| Ani Pharmaceuticals, INC. | $109.58 | 2023-2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $103.20 | 2023-2025 | Opsumit, Opsynvi |
| Hikma Pharmaceuticals USA | $95.20 | 2019-2020 | |
| Genzyme Corporation | $94.83 | 2020-2024 | |
| Radius Health, INC. | $93.97 | 2019-2025 | Tymlos |
| Octapharma USA, INC. | $86.41 | 2024-2025 | Octagam Immune Globulin (Human) |
| Fresenius Kabi USA, LLC | $77.99 | 2023-2025 | Idacio |
| Merck Sharp & Dohme LLC | $62.60 | 2020-2021 | |
| Gilead Sciences, INC. | $60.59 | 2019-2020 | |
| Pharming Healthcare, INC. | $50.61 | 2024-2025 | Ruconest |
| Medexus Pharma, INC. | $43.67 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $42.91 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $40.24 | 2022-2023 | Givlaari |
| Regeneron Healthcare Solutions, INC. | $35.79 | 2019 | |
| Shorla Oncology INC. | $32.20 | 2024 | |
| Sandoz INC. | $29.03 | 2023 | Hyrimoz |
| Kyowa Kirin, INC. | $23.84 | 2023 | Crysvita |
| Scilex Pharmaceuticals INC. | $22.97 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $18.00 | 2024 | Arcalyst |
| Avion Pharmaceuticals | $13.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harjinder Chowdhary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.